Bristol-Myers Squibb clears Russell growth benchmarks reshuffle, shares hold near recent gains

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-29, 14:06.

Bristol-Myers Squibb (US1078421011) begins the new week in New York with fresh index news around the Russell family and a stable share price picture on the NYSE. Market data from Friday puts the BMY shares around 57.52 US dollars, close to recent highs in the large-cap pharma peer group including Pfizer and Merck.MarketScreener benchmark overview

Russell growth benchmarks adjust

Index provider FTSE Russell has removed Bristol-Myers Squibb from both the Russell Top 200 Growth and Russell 3000 Growth benchmarks in the latest annual reconstitution, according to recent benchmark notes summarizing membership changes for US drugmakers.MarketScreener Russell changes report The company remains in the broader Russell 3000 universe and the S&P 500, but its exclusion from these specific growth segments modestly shifts its profile in factor-based portfolios.

The benchmark notes show Bristol-Myers Squibb’s last close at 57.52 US dollars, with the shares up about 3.85 percent on the day of the index announcement, underlining that the growth label adjustment did not trigger a marked negative reaction in the NYSE trading session.Benchmark price snapshot

Analyst view and sector comparison

Alongside the benchmark reshuffle, Wall Street research continues to refine its stance on Bristol-Myers Squibb. Citi recently raised its price target on the shares from 64 to 66 US dollars while maintaining a Neutral rating, pointing to a balanced risk-reward profile as the company works through patent expiries and launches new oncology and immunology drugs.Citi update via sector comparison The same analysis notes that Bristol-Myers trails Johnson & Johnson on diversification but retains a strong position in specialty therapeutics.

Consensus figures compiled by MarketScreener show an average target price around 63.08 US dollars for Bristol-Myers Squibb, implying limited upside from the latest 57.52 dollar close and reinforcing Citi’s neutral tone.MarketScreener consensus snapshot Within the pharmaceuticals sector, the stock trades at a mid-range valuation, with a trailing price-earnings multiple in the mid-teens and a dividend yield anchored by the 0.63 dollar quarterly payout.

The therapies behind the stock

Bristol-Myers Squibb generates most of its revenue from specialty prescription medicines in oncology, hematology, cardiovascular and immunology. Key brands include the cancer immunotherapy Opdivo, the blood thinner Eliquis, the multiple myeloma treatment Revlimid and newer assets such as the plaque psoriasis drug Sotyktu, which compete directly with products from peers like Johnson & Johnson and Takeda.Company product portfolio overview

Where the Bristol-Myers Squibb shares trade

The Bristol-Myers Squibb shares (US1078421011) trade on the NYSE under the ticker BMY, with the last verified close on 2026-06-26 at 57.52 US dollars based on U.S. exchange data.

Disclaimer: This article is for informational purposes only and does not contain investment advice, personal recommendations or an offer to buy or sell securities. All data are based on sources deemed reliable but may be updated or corrected without notice.